RNS & Investor News

Allotment of shares to employee benefit trust and Total Voting Rights

12 August 2020

Collagen Solutions plc (AIM: COS), the developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announces that, on 11 August 2020 it allotted 3,195,929 new ordinary shares of £0.01 each in the Company (“New Ordinary Shares”) to the trustee of the Collagen Solutions plc Employee Benefit Trust (the “Trust”) in order to allow the Trust to satisfy awards previously made under the Collagen Solutions plc Deferred Bonus Plan as previously announced on 3 October 2019.

It is anticipated that the New Ordinary Shares (which will rank pari passu in all respects with the existing ordinary shares of the Company) will be admitted to trading on AIM on or around 17 August 2020 (“Admission”). Following Admission, the Company’s issued share capital will comprise 446,878,910 ordinary shares with voting rights and that figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules. The Company does not hold any shares in treasury.


For further information please contact:

Collagen Solutions Plc
Jamal Rushdy, CEO
Hilary Spence, CFO
Via Walbrook

Cenkos Securities Plc (Nominated Adviser and Broker)
Giles Balleny (Corporate Finance)
Stephen Keys

Tel: 0207 397 8900

Walbrook PR Ltd (Financial PR)
Anna Dunphy
Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001

Global Delivery

Qualified shippers ensure the product reaches its destination safely within client time and temperature protocols around the globe.

Quality Certifications

logo_gmp edqm logo_bsi logo_bsi_2

Need a Custom Formulation?

We will formulate a product specifically for your application.
Please contact us to discuss your requirements for collagen biomaterials.

Contact Us